Ocular Therapeutix (NASDAQ:OCUL) announces positive
results from a Phase 1 clinical trial evaluating a single insertion of
OTX-TIC in patients with primary open-angle glaucoma or ocular
hypertension. The data are being presented at the Glaucoma 360
conference in San Francisco.
Results from the first two fully enrolled cohorts
(n=5 and n=4, respectively) showed decreased average intraocular
pressure (IOP) values that were sustained through the study period and
beyond (18 months in one participant).
No serious adverse events were reported.
OTX-TIC is a bioresorbable implant containing
micronized travoprost that is injected into the anterior chamber of the
eye, releasing the drug over a four-to-six-month timeframe.
https://seekingalpha.com/news/3539669-ocular-therapeutix-up-11-premarket-on-encouraging-otx-tic-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.